Q203 is primarily investigated for its potential in treating tuberculosis (TB), particularly drug-resistant strains. It works by inhibiting the cytochrome bc1 complex, a critical component of the bacterial respiratory chain, thereby disrupting energy production in Mycobacterium tuberculosis. This mechanism makes it a promising candidate for inclusion in TB drug regimens, especially in cases where first-line treatments fail. Research is ongoing to evaluate its efficacy, safety, and potential combination with other anti-TB drugs to enhance therapeutic outcomes. Its development represents a significant step forward in addressing the global challenge of multidrug-resistant TB.